Ovarian cancer, often a "silent killer," is the 8th most common cancer in women globally and the third in India. Early ...

Hua-Ying Fan, PhD, hopes that her team's latest discovery could help the almost 21,000 people who are expected to receive an ...

Wistar Institute scientist Maureen Murphy wants to solve a decades-long mystery: Why is ovarian cancer often resistant to ...

FZOCUS-1 assessed the safety and efficacy of fuzuloparib alone and in combination with apatinib for patients with newly diagnosed or advanced ovarian cancer.

Inherited changes in the tumor suppressor genes BRCA1 and BRCA2, raise lifetime risk substantially. For ovarian cancer, the ...

Ovarian cancer, often called the “silent killer,” continues to be one of the most dangerous threats to women’s health, ...

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

First-line PARP inhibitor maintenance after platinum chemotherapy reduces progression risk in certain patients with ovarian ...

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.

Ovarian cancer is often advanced at the time of diagnosis. Debulking is a surgical procedure that may prevent or delay disease progression. Debulking is a type of surgery that removes as many ovarian ...